Adalimumab

Abstract

Adalimumab, an entirely human monoclonal antibody, specifically blocks the cell-surface receptor relationship of tumor necrosis factor-alpha (TNF-α) with p55 and p75 TNF-α, thereby suppressing the biological activity of TNF-α. It received FDA approval in 2008 for the treatment of moderate to severe psoriasis that does not respond to conventional treatments or for which these treatments are contraindicated or intolerable. Adalimumab is also indicated for the treatment of moderate to severe chronic plaque psoriasis in children aged 4 and over. Administered via subcutaneous injections, adalimumab is also suitable for intermittent use under certain conditions.

Keywords

• adalimumab
• tnf-α
• psoriasis